Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021)
Elicio Therapeutics' (ELTX) quarterly Gross Margin came in at 98.33% in Q4 2021, up 2578.0% YoY from 3.67% in Q4 2020, and down 1.67% on a QoQ basis from 100.0% in Q3 2021.
Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021) Analysis & Trends
Elicio Therapeutics (ELTX) has 2 years of Gross Margin data on file, last reported at 98.33% in Q4 2021.
- Quarterly Gross Margin rose 2578.0% year-over-year to 98.33% in Q4 2021, while the trailing twelve-month figure through Dec 2021 was 98.47% (up 5753.0% YoY) and the FY2022 annual result came in at 100.0%, up 153.0% from the prior year.
- Gross Margin retreated to 98.33% in Q4 2021, from 100.0% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q1 2021 to a low of 54.32% in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 98.33% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 72.55% |
| Sep 30, 2020 | 57.92% |
| Jun 30, 2020 | 54.32% |